Patents by Inventor Manuel Buttini

Manuel Buttini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150353631
    Abstract: The present invention provides antibodies directed against C-terminal and central epitopes of A? that preferentially bind compact plaques relative to diffuse plaques. The invention also provides methods of treating patients to reduce or eliminate the presence of compact plaques of A? and associated symptoms.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 10, 2015
    Inventors: Manuel Buttini, Ming Chen, Shyra Gardai
  • Patent number: 8506959
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: August 13, 2013
    Assignees: Neotope Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20080014194
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: April 6, 2007
    Publication date: January 17, 2008
    Applicants: Elan Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Dale Schenk, Kcote Games, Manuel Buttini, Tamie Chilcote, Edward Rockenstein, Eliezar Masliah
  • Publication number: 20060058233
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: July 19, 2005
    Publication date: March 16, 2006
    Applicants: Elan Pharmaceuticals, Inc., Regents of the University of California
    Inventors: Dale Schenk, Eliezer Masliah, Manuel Buttini, Tamie Chilcote, Edward Rockenstein, Kate Games
  • Patent number: 6046381
    Abstract: The present invention features non-human transgenic animal models for gene function, wherein the transgenic animal is characterized by having altered endogenous apolipoprotein E gene function and a transgene for an exogenous human apolipoprotein E isoform. The transgenic animals may be either homozygous or heterozygous for the transgene. The invention also features methods for using non-human transgenic animal models for the study of apolipoprotein E-mediated pathologies and the identification of compounds and therapies for such pathologies.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: April 4, 2000
    Assignee: The Regents of the University of California
    Inventors: Lennart Mucke, Jacob Raber, Manuel Buttini, Robert W. Mahley, Robert E. Pitas